Hylan G-F 20 (Synvisc, Synvisc One) is a drug prescribed for treating pain caused by osteoarthritis of the knee. Synovial fluid is a fluid in the joints that act as a lubricant and shock absorber. Patients with osteoarthritis (OA) have thinner synovial fluid than normal. Synvisc is an elastic fluid that acts as a lubricant and shock absorber, and thus helps restore the shock absorbing effect of the fluid within the knee. This drug is administered as an injection of 16 mg/2 ml and 48 mg/6ml by a doctor or other healthcare professional. There are no known drug interactions with Synvisc. There aren't any adequate drug studies for Synvisc during pregnancy or while breastfeeding . Synvisc is secreted into breast milk.
IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.